OVERVIEW
Join us for a live, interactive, 90-minute symposium focused on the use of HER2-targeted therapy for the treatment of biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA). Expert faculty will discuss the rationale for the use of HER2-targeted therapies in BTC and GEA, recent clinical trial data, and guidelines and recommendations for incorporating HER2-targeted therapies into clinical practice. The gastrointestinal expert panel will be joined by a patient advocate to emphasize the importance of the patient's voice in making clinical decisions. The experts will discuss ways to strategize considerations for treating and managing patients with BTC and GEA as well as emphasizing the importance of the role of the multidisciplinary team to optimize care for patients.
GOAL STATEMENT
The goal of this activity is for learners to be better able to understand emerging anti-HER2 therapies used to manage GEA and BTC and to determine the most appropriate communication strategies to ensure a patient-centric approach to care.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the[LIST][ITEM]Mechanism of action of emerging anti-HER2 therapies being considered for the management of GEA and BTC[ITEM]Biological rationale for utilizing bispecific antibodies to target HER2 in gastrointestinal malignancies[ITEM]Clinical utility of the emerging anti-HER2 therapies for the management of GEA and BTC based on emerging clinical data[/LIST]Demonstrate greater confidence in their ability to[LIST][ITEM]Understand the role of emerging HER2-targeting therapies in the management of GEA and BTC[ITEM]Determine the most appropriate communication strategies to ensure a patient-centric approach to care
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.5 [bold][italic]AMA PRA Category 1 Credits™[/italic][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
InterContinental San Francisco
Grand Ballroom AB - 3rd floor
888 Howard St Grand Ballroom AB - 3rd floor
San Francisco, California, 94103
United States
Not an official event of the 2024 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.
Supported by an independent educational grant from [bold]Jazz Pharmaceuticals[/bold].